Skip to main content
. 2021 Jul 23;9:695841. doi: 10.3389/fped.2021.695841

Table 2.

Ophthalmologic characteristics of the population enrolled in the “surgery group”.

1st int. 2nd int. 3rd int. 4th int. Baseline a Last follow-up b
ID Gen Age (y) Int. Age (y) Int. Age (y) Int. Age (y) Int. Near α (PD) c Dist. α (PD) c RE SE (D) LE SE (D) RE Cyl (D) LE Cyl (D) Near α (PD) c Dist. α (PD) c RE SE (D) LE SE (D) RE Cyl (D) LE Cyl (D) Stereoacuity (“) d
37 F 2 H 30 4.75 5.00 2.50 3.00 20 14 5.00 5.25 3.00 3.50
38 M 2 H 35 2.13 1.63 1.25 1.25 0 −8 3.25 3.13 2.50 1.75
39 M 3 H 40 30 2.00 2.50 8 8 1.25 3.50 0.50 1.50 60
40 M 3 H 40 30 3.75 3.00 2.50 2.00 −4 −6 5.38 4.13 3.75 2.25
41 M 3 H 35 30 2.50 3.00 −2 −6 4.13 4.13 1.25 3.75 140
42 M 3 H 35 35 0.75 0.75 14 16 0.25 0.25 0.50
43 M 3 H 35 35 4.50 4.38 0.50 0.75 14 4 5.00 5.00 0.50
44 F 3 H 35 3.75 3.25 1.50 1.00 2 2 4.88 4.25 1.75 0.50
45 F 3 H 35 30 2.50 2.75 0.50 4 2 3.00 3.00 0.50 0.50 100
46 M 3 H 45 3.00 3.00 3.00 1.00 16 14 3.75 3.25 2.50 1.50
47 F 3 H 30 3.50 3.75 0.50 0.50 4 6 3.25 2.75 1.00
48 M 3 H 35 30 4.75 5.00 0.50 0.50 0 −6 5.25 5.75 1.00
49 F 3 H 30 2.25 4.63 0.50 1.25 0 0 4.00 6.13 1.25
50 M 3 H 40 3.88 5.00 0.75 0 0 4.75 5.25 1.50 1.00
51 F 3 H 35 30 3.75 3.00 6 0 6.50 6.00 1.00 1.00
52 F 3 H 40 35 1.13 0.50 0.75 6 0 0.50 −0.25 0.50
53 F 3 H 30 2.25 2.50 1.00 6 6 1.00 2.38 2.00 0.75
54 M 3 H 30 2.00 2.00 0 0 2.25 2.00 0.50 0.50 40
55 F 3 H 30 30 4.50 4.63 0.50 0.75 0 0 4.88 5.63 1.75 1.75
56 M 4 H 35 35 3.38 2.88 1.75 1.25 0 −2 4.50 3.88 2.00 1.75
57 M 4 H 35 35 3.50 4.25 0.50 0.50 2 0 4.50 5.25 140
58 F 4 H 35 35 1.00 1.00 0.50 1.00 10 10 1.25 2.50 1.00 0.50
59 F 4 H 40 40 1.25 1.00 4 0 1.50 1.50 0.50
60 M 4 H 35 4.38 3.88 1.25 1.75 4 2 4.50 4.00 2.00 2.00
61 M 4 H 35 30 2.00 2.00 12 2 2.50 2.75
62 F 4 H 30 30 2.25 2.13 3.00 2.75 −2 −4 −0.63 −2.38 2.75 2.75
63 M 2 H 3 H 30 2.00 1.75 0.50 6 2 1.50 0.50
64 F 2 H 10 H 30 30 2.88 2.50 0.75 0 0 0.63 0.00 1.25
65 M 3 H 5 H 30 2.50 2.75 1.50 1.50 4 0 0.38 1.25 1.75 1.50
66 F 4 H 9 H 35 35 4.00 4.00 1.00 1.50 14 14 4.38 4.63 2.75 3.25
67 M 4 H 8 H 40 35 1.38 1.88 0.75 1.25 6 4 3.00 3.38 1.00 1.75 140
68 M 3 H 4 H 10 IO 40 4.75 4.88 0.50 0.75 −2 −4 5.25 5.00 0.50 0.50 140
69 F 2 H 7 IO 40 1.25 1.38 0.75 0 0 −2.50 −2.50 1.50 140
70 F 2 H 4 IO 9 H 35 30 4.50 4.50 2.00 2.50 25 20 4.00 5.13 2.50 2.75
71 M 2 H 9 H+IO 40 2.25 1.63 1.00 0.75 6 0 2.75 1.88 1.00 0.75
72 F 3 H 6 H+IO 35 30 1.63 1.63 1.25 0.75 4 4 3.38 2.38 1.25 2.25
73 F 3 H 5 H+IO 35 4.00 3.75 1.50 1.50 −10 −4 4.50 4.63 1.50 1.25
74 M 4 H 5 H+IO 50 45 0.25 1.00 2.00 1.00 18 16 −1.75 −3.00 0.50 1.00
75 F 3 H+IO 45 4.00 4.38 0.50 1.25 16 10 5.00 4.75 1.00 1.00
76 M 3 H+IO 40 3.50 3.50 2.00 2.00 −4 −2 5.13 5.63 1.25 1.25
77 F 3 H+IO 45 2.38 2.88 0.75 1.25 20 14 2.25 2.00 1.50 1.00
78 M 4 H+IO 40 30 1.88 1.50 0.75 1.00 10 6 2.50 3.00 1.00 2.00 100
79 M 2 H+IO 4 H 40 2.75 3.25 2.50 2.50 14 14 3.50 2.88 2.50 2.25
80 M 3 H+IO 9 H 30 30 1.50 1.50 0.50 6 8 0.75 −2.75 80
81 M 3 H+IO 4 H 50 0.75 0.63 1.00 0.75 −6 −2 −2.50 −3.25 1.50 1.00 140
82 F 3 H+IO 4 H 30 30 0.25 0.38 0.50 0.75 14 12 1.63 1.63 0.75 0.75
83 M 4 H+IO 6 H 30 1.63 1.00 1.25 1.00 8 8 0.25 1.38 1.25
84 F 4 H+IO 6 H 35 30 2.50 2.38 1.00 0.75 10 12 2.75 2.75 2.50 2.00
85 M 4 H+IO 4 H 35 35 3.13 3.50 1.25 2.00 −8 −8 3.38 4.00 1.25 2.00 140
86 M 4 H+IO 13 SR 40 30 1.00 0.50 10 8 −2.75 −1.63 0.50 0.75 140

ID, identification number; Gen, gender; y, years; Int., intervention; Dist., distance; α, angle of deviation; PD, prism diopters; D, diopters; RE, right eye; LE, left eye; SE, spherical equivalent; Cyl, cylinder; ″, seconds of arc; M, male, F, female; BT: chemodenervation with botulinum toxin; H: horizontal muscle surgery; IO: inferior oblique muscle recession; SR, superior rectus muscle recession.

a

The day before the first intervention;

b

at least 5 years after the last intervention;

c

positive numbers refer to esodeviations; negative to exodeviations;

d

Titmus test <160″.